Core Insights - The 2025 European Hematology Association (EHA) annual meeting showcased nearly 60 clinical research results from four Chinese innovative drug companies, highlighting China's scientific strength in developing innovative therapies for hematological cancers [1] - The collective breakthroughs of these companies at international platforms like ASCO and EHA signify a strategic shift in China's innovative drug industry from "fast following" to "independent innovation" [1] - The EHA annual meeting is a significant academic event in the global hematology field, attracting over 10,000 professionals from more than 100 countries [1] Company Highlights - BeiGene presented four major oral reports at the EHA meeting, demonstrating key breakthroughs in its pipeline for hematological cancer treatments [1] - The next-generation BCL2 inhibitor, Sotorasib, combined with Baiyueze®, achieved total response rates of 96% and 79% for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma, respectively [2] - The potential first-in-class BTK degrader BGB-16673 showed promising early data for treating CLL and Waldenström's macroglobulinemia [2] - Innovent Biologics had 25 studies presented as posters at the EHA meeting, focusing on new BTK inhibitors and BCL2 inhibitors for various lymphomas [2] Research Developments - The combination of Mesutoclax and Obinutuzumab for first-line treatment of CLL/SLL showed a total response rate of 97.6% in a cohort of 42 newly diagnosed patients, with a registration phase III clinical trial now underway [3] - Dizhizhi Pharmaceuticals showcased multiple research advancements covering T-cell and B-cell lymphomas, including the JAK1 inhibitor, Gyrizhe®, which demonstrated effective maintenance treatment in peripheral T-cell lymphoma [3] - Micu Biotech presented 19 new research results on its selective HDAC inhibitor, Sitarabin, across various hematological malignancies, indicating significant tumor response and broad application prospects [4]